Correlation Between Erasca and NGM Biopharmaceutica
Can any of the company-specific risk be diversified away by investing in both Erasca and NGM Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Erasca and NGM Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Erasca Inc and NGM Biopharmaceuticals, you can compare the effects of market volatilities on Erasca and NGM Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Erasca with a short position of NGM Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Erasca and NGM Biopharmaceutica.
Diversification Opportunities for Erasca and NGM Biopharmaceutica
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Erasca and NGM is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Erasca Inc and NGM Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NGM Biopharmaceuticals and Erasca is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Erasca Inc are associated (or correlated) with NGM Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NGM Biopharmaceuticals has no effect on the direction of Erasca i.e., Erasca and NGM Biopharmaceutica go up and down completely randomly.
Pair Corralation between Erasca and NGM Biopharmaceutica
If you would invest (100.00) in NGM Biopharmaceuticals on December 28, 2024 and sell it today you would earn a total of 100.00 from holding NGM Biopharmaceuticals or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Erasca Inc vs. NGM Biopharmaceuticals
Performance |
Timeline |
Erasca Inc |
NGM Biopharmaceuticals |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Erasca and NGM Biopharmaceutica Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Erasca and NGM Biopharmaceutica
The main advantage of trading using opposite Erasca and NGM Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Erasca position performs unexpectedly, NGM Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NGM Biopharmaceutica will offset losses from the drop in NGM Biopharmaceutica's long position.Erasca vs. Day One Biopharmaceuticals | Erasca vs. Mirum Pharmaceuticals | Erasca vs. Rocket Pharmaceuticals | Erasca vs. Avidity Biosciences |
NGM Biopharmaceutica vs. Instil Bio | NGM Biopharmaceutica vs. Achilles Therapeutics PLC | NGM Biopharmaceutica vs. NextCure | NGM Biopharmaceutica vs. Assembly Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Valuation Check real value of public entities based on technical and fundamental data |